Curapath - Polymer & lipids - Nanoparticles - Bioconjugation

Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in polymer and lipid-based non-viral drug delivery systems and their components. This includes the development and manufacturing of polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), and advanced drug conjugation strategies. We support regulated biotech, pharmaceutical, and medical device programs from early development through GMP and commercial manufacturing.

Our offer combines off-the-shelf R&D and GMP-grade materials, as well as custom development services, enabling our partners to progress efficiently from early feasibility to scalable and regulatory-ready manufacturing. Our solutions include PEG alternatives, active targeting strategies for lipid nanoparticles (LNPs), and tunable transfection reagents, all designed with a strong focus on manufacturability, reproducibility, and long-term regulatory compliance, supporting both clinical and commercial supply of advanced delivery technologies.